Jordana Joy, Editor

Cecelia Koetting, the EnVision Summit chair for optometry, OD, FAAO, DipABO, gave a sneak peak into the CE and networking opportunities at the conference.

In recent months, developments have ranged from regulatory setbacks to real-world data releases.

Derek N. Cunningham, OD, FAAO, details candidate selection, mechanism of action, and patient education for the new eye drop.

Formerly known as Brimochol PF, the dual-agent eye drop is now the first and only of its kind for the treatment of presbyopia in adults.

Bisant A. Labib, OD, FAAO, DipAAO, gives her insights on the causes and management of anterior uveitis during Island Eyes 2026.

Benjamin P. Casella, OD, FAAO, shares perspectives on the most impactful glaucoma developments from the past year and the future role of interventional and personalized care.

Keeping a pulse on current developments has helped optometrists look to the future

ODs are gearing up for anticipated advancements in specialty lens and lenses for myopia management and patients with astigmatism.

Kuzniar's OGSLS 2026 poster presentation provides a follow-up to previous fitting findings for the Zenlens Chroma HOA lens.

Jason Jedlicka, OD, FAAO, talks through a presentation he gave during last week's conference.

Previously, the EDOF technology was specifically limited to intraocular lenses.

Susan Gromacki, OD, MS, FAAO, FSLS, details her presentation given at this year's conference.

Jamie Kuzniar, OD, FAAO, FSLS, details a poster presentation that served as a follow-up to results of previous fittings of Zenlens Chroma HOA (Bausch + Lomb).

Jason Jedlicka, OD, overviews his poster, “A Custom Wavefront-Guided Scleral Lens System For Higher Order Aberrations: Real-World Early Experience From a Retrospective Multicenter Case Review.”

New clinical data and trial updates closed out 2025.

The lens was developed in collaboration with Brien Holden Vision Institute (BHVI).

Kramer, OD, FAAO, FSLS, presented alongside Kelsea Skidmore, OD, MS; Vivien Tse, OD; and Elaine Chen, OD, at this year's conference.

Edward Choy, partner at Sho Eyeworks, shares success stories of private practices creating their own eyewear frame line.

Edward Choy, partner at Sho Eyeworks, advises practice owners on the fence of developing their own brand to dive in.

Edward Choy, partner at Sho Eyeworks, and Diana Canto-Sims, OD, discuss the company's price points and partner subscription options.

An overview of the top 10 stories from eye care for 2025.

The researchers conducted a literature search of MEDLINE and Embase, PubMed, Cochrane Library, and Web of Sciences databases from 2003 to 2023.

Edward Choy, partner at Sho Eyeworks, and Diana Canto-Sims, OD, drive home the importance of profitability in creating an eyewear brand.

The PDUFA target action date is June 30, 2026.

The organization reaffirmed that it stands by myopia defined as a chronic, progression disease.

Isocyclosporin is a dual inhibitor of transient receptor potential cation channel, mucolipin subfamily, member 2 (TRPML2), and calcineurin.

Nancy Gries, export sales manager at Logoproject Eyewear, stated that a private label eyewear brand can keep a practice up to date with trends.

Optometrists have their eyes set on ocular surface disease treatment and contact lens technology advancement.

Nancy Gries, export sales manager at Logoproject Eyewear, discusses the company's process for creating a private label eyewear brand, from logo design to final product.

The eye care providers authored an opinion article that has been published in "The Ocular Surface."